

NOTICE OF SHARE CAPITAL REDUCTION BY THE COMPANY

ONCOMATRYX BIOPHARMA, S.A.

In compliance with the provisions of Article 319 of the Consolidated Text of the Capital Companies Act, it is hereby announced that the Extraordinary General Meeting of Oncomatryx Biopharma, S.A., held on September 16, 2026, with its registered office located in Derio (Bizkaia), Parque Tecnológico de Bizkaia, 801 B 2º, (zip code 48160), with tax identification number (NIF) A 95586780 (the "Company"), unanimously adopted, in accordance with the Capital Companies Act and its bylaws, the resolution to proceed with a reduction of the share capital through the redemption of treasury shares.

With regard to the capital reduction to retire treasury shares, it was agreed to reduce the share capital by 140,565.60 euros through the retirement of 468,552 treasury shares with a par value of 0.30 euros each, all of the same class. These shares are held by the company in its treasury stock and were previously acquired by the company through a purchase agreement.

The reduction of share capital through the redemption of the Company's treasury shares will not result in the return of capital contributions to shareholders, as the Company itself is the owner of the shares to be redeemed. Therefore, the sole purpose of the aforementioned reduction will be the redemption of such treasury shares.

As a result of the redemption of these treasury shares, a reduction in the amount of share capital equal to the par value of the redeemed shares is recorded, that is, in the amount of 140,565.60 euros. The difference between the acquisition price and the par value of the aforementioned shares is charged against voluntary reserves under the same requirements as those required for the reduction of share capital.

As a result of the agreed-upon capital reduction, Article 6 of the Articles of Incorporation will be amended and shall henceforth read as follows:

"Article 6.—The share capital amounts to three million six hundred sixty-two thousand nine hundred eleven euros and eighty cents (€3,662,911.80), represented by twelve million two hundred nine thousand seven hundred six (12,209,706) registered common shares, each with a par value of thirty cents (€0.30), all belonging to a single class and series and conferring the same rights and obligations, fully subscribed and paid up."

The foregoing is made public so that the Company's creditors may exercise their right to object to the aforementioned reduction in share capital within a period of one (1) month, under the terms set forth in Articles 334 and 336 of the Capital Companies Act.

Derio (Bizkaia), September 29, 2026. – Mr. Luis Alba Ferré, secretary non director of the Board of Directors of Oncomatrix Biopharma, S.A.